Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArcticZymes Technologies ASA ( (DE:B4V) ) has issued an update.
ArcticZymes Technologies ASA has expanded its GMP product range by introducing M-SAN HQ GMP, a new GMP grade nuclease designed for viral vector manufacturing. This product is tailored to meet the needs of advanced therapies and vaccine platforms by enabling efficient enzymatic host cell DNA removal under physiological salt conditions. The launch addresses the growing demand for reducing nuclease and host cell DNA contamination in therapeutic products, supporting the development of future therapies such as in vivo CAR-T. This strategic move enhances ArcticZymes’ position in the biomanufacturing industry by offering a technically advanced and compliant solution that integrates seamlessly into biomanufacturing workflows.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a Norwegian life sciences company that specializes in developing, manufacturing, and commercializing novel recombinant enzymes for molecular research, In Vitro Diagnostics (IVD), and biomanufacturing. The company is headquartered in Tromsø, Norway, and operates from the SIVA Science Park. ArcticZymes holds a substantial portfolio of patents to protect its intellectual property and capabilities.
YTD Price Performance: 25.56%
Average Trading Volume: 33,841
Current Market Cap: NOK855.4M
Learn more about B4V stock on TipRanks’ Stock Analysis page.